共 212 条
[1]
Tsumoto K(2019)Future perspectives of therapeutic monoclonal antibodies Immunotherapy 11 119-127
[2]
Isozaki Y(2015)The therapeutic monoclonal antibody market mAbs 7 9-14
[3]
Yagami H(2017)Pharmacokinetics of monoclonal antibodies CPT Pharmacometrics Syst Pharmacol 6 576-588
[4]
Tomita M(2018)Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release 286 301-314
[5]
Ecker DM(2010)Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Nat Biotechnol 28 1203-1207
[6]
Jones SD(2013)Engineered monoclonal antibody with novel antigen-sweeping activity in vivo PLoS ONE 8 e63236-132
[7]
Levine HL(2016)PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model Drug Metab Pharmacokinet 31 123-151
[8]
Ryman JT(2016)Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation Immunol Rev 270 132-1561
[9]
Meibohm B(2013)Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase Br J Cancer 109 1556-41
[10]
Viola M(2019)Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering Drug Metab Pharmacokinet 34 25-63